Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/194013
Revisiting the bioavailability of flavan-3-ols in humans: A systematic review and comprehensive data analysis
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
This systematic review summarizes findings from human studies investigating the different routes of absorption, metabolism, distribution and excretion (ADME) of dietary flavan-3-ols and their circulating metabolites in healthy subjects. Literature searches were performed in PubMed, Scopus and the Web of Science. Human intervention studies using single and/or multiple intake of flavan-3-ols from food, extracts, and pure compounds were included. Forty-nine human intervention studies met inclusion criteria. Up to 180 metabolites were quantified from blood and urine samples following intake of flavan-3-ols, mainly as phase 2 conjugates of microbial catabolites (n =97), with phenyl-γ-valerolactones being the most representative ones (n =34). Phase 2 conjugates of monomers and phenyl-γ-valerolactones, the main compounds in both plasma and urine, reached two peak plasma concentrations (Cmax) of 260 and 88 nmol/L at 1.8 and 5.3 h (Tmax) after flavan-3-ol intake. They contributed to the bioavailability of flavan-3-ols for over 20%. Mean bioavailability for flavan-3-ols was moderate (31 ±23%, n bioavailability values =20), and it seems to be scarcely affected by the amount of ingested compounds. While intra- and inter-source differences in flavan-3-ol bioavailability emerged, mean flavan-3-ol bioavailability was 82% (n =1) and 63% (n =2) after ()-epicatechin and nut (hazelnuts, almonds) intake, respectively, followed by 25% after consumption of tea (n =7), cocoa (n =5), apples (n =3) and grape (n =2). This highlights the need to better clarify the metabolic yield with which monomer flavan-3-ols and proanthocyanidins are metabolized in humans. This work clarified in a comprehensive way for the first time the ADME of a (poly)phenol family, highlighting the pool of circulating compounds that might be determinants of the putative beneficial effects linked to flavan-3-ol intake. Lastly, methodological inputs for implementing well- designed human and experimental model studies were provided.
Matèries
Matèries (anglès)
Citació
Citació
DI PEDE, Giuseppe, MENA, Pedro, BRESCIANI, Letizia, ACHOUR, Mariem, LAMUELA RAVENTÓS, Rosa ma., ESTRUCH RIBA, Ramon, LANDBERG, Rikard, KULLING, Sabine, WISHART, David s., RODRÍGUEZ-MATEOS, Ana, CROZIER, Alan, MANACH, Claudine, DEL RIO, Daniele. Revisiting the bioavailability of flavan-3-ols in humans: A systematic review and comprehensive data analysis. _Molecular Aspects of Medicine_. 2023. Vol. 89. [consulta: 23 de gener de 2026]. ISSN: 0098-2997. [Disponible a: https://hdl.handle.net/2445/194013]